Mayo Clinic's Biobank is preparing to start sending the genetic code of 100,000 patients to a private drug maker as part of an "exchange."Once the DNA is sequenced, it will use the data in the development of new drugs and possibly sell the anonymous data to other companies for their research. Also, Mayo will be returned the data from its patient samples to use its own research.
External News Article:
Add reference to external site news article